KFSH&RC, KAMC, and AUH run the GCC's only structured adult sickle cell disease programmes for a 200,000-250,000-patient population, and Eastern Province's 12+ MOH regional centres anchor the referral network feeding them.
GCC sickle cell disease expertise concentrates around a small number of specialist centres, not a broad regional field. KFSH&RC, KAMC, and AUH are the only institutions maintaining structured adult SCD programmes across an estimated 200,000-250,000 GCC patients; most other GCC hospitals manage adult SCD within general internal medicine without dedicated haematology oversight. The KFSH&RC Dammam flagship anchors 12+ MOH regional centres in Eastern Province, home to 80,000-100,000 of Saudi Arabia's 140,000-200,000 patients and a 6-7% carrier rate, the epicentre of the region's disease burden. That kind of institutional concentration around a single flagship-plus-network structure does not happen without an established referral pathway from paediatric to adult haematology. Our KOL Universe gate (K1) starts by mapping exactly this institutional concentration before any individual physician is scored.
That structure changes how AXLRx tiers influence across the GCC. A haematologist affiliated with KFSH&RC, KAMC, or AUH, particularly one engaged in adult-transition care or SFDA registration review, carries different scientific weight than one working at a regional MOH centre without dedicated haematology oversight, and our Tier Classification gate (K2) scores that distinction directly, alongside institutional role in national premarital-screening programme delivery. No named individual enters the workbook without a verification tag; every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a centre with no real influence over SFDA formulary review or NPHC national-programme decisions, which is exactly what the K1-K6 gate structure is built to prevent.
The GCC sickle cell disease institutional network — three structured adult-care centres plus the wider regional network
| Institution | Market | Role in Network |
|---|---|---|
| King Faisal Specialist Hospital and Research Centre (KFSH&RC), Dammam | Saudi Arabia | Flagship structured adult SCD programme, Eastern Province epicentre |
| King Abdulaziz Medical City (KAMC) | Saudi Arabia | Structured adult SCD programme |
| AUH | GCC | Structured adult SCD programme |
| Hamad Medical Corporation | Qatar | National SCD referral centre |
| Cleveland Clinic Abu Dhabi | UAE | Specialist haematology referral centre |
| Sheikh Shakhbout Medical City | UAE | Specialist haematology referral centre |
Sources: GCC SCD network survey 2022 (KFSH&RC, KAMC, AUH); KFSH&RC SCD outcomes registry; NPHC Saudi SCD programme 2022; Al-Qurashi MM, Eur J Haematol 2010.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The KFSH&RC, KAMC, and AUH concentration structure
- the KFSH&RC Dammam flagship and 12+ MOH regional centre network
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- SFDA registration-review and premarital-screening-programme role weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the KFSH&RC, KAMC, and AUH concentration structure before the rest of the workbook is built out
- Every GCC sickle cell disease KOL sized and sourced from publication and institutional-affiliation data
- The KFSH&RC Dammam flagship and 12+ MOH regional centre network as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across SFDA registration-review role and premarital-screening-programme engagement
- What separates a Tier 1 KOL from a high-volume regional prescriber
- Influence inputs: publication authorship, national-programme role, institutional adult-transition leadership
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across Eastern Province, Riyadh, and the wider GCC
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond Saudi Arabia, across Qatar and the UAE
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
GCC sickle cell disease KOL sources: the GCC SCD network survey 2022 (KFSH&RC, KAMC, AUH), the KFSH&RC SCD outcomes registry, and NPHC Saudi SCD programme documentation 2022.
- Institutional concentration structure (KFSH&RC, KAMC, AUH) verified against the GCC SCD network survey 2022
- Eastern Province patient concentration (80,000-100,000 of 140,000-200,000 Saudi patients) verified against the KFSH&RC SCD outcomes registry and NPHC Saudi SCD programme 2022
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC sickle cell disease specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.